Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
1. An isolated antibody that binds human CCR8, wherein the antibody comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 84 or 100, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 86, a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 87, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 88, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 89.
2. The isolated antibody of claim 1 , wherein the antibody is a monoclonal antibody.
3. The isolated antibody of claim 1 , wherein the antibody is a humanized antibody.
4. The isolated antibody of claim 1 , wherein the antibody is a full-length antibody.
5. The isolated antibody of claim 1 , wherein the antibody is an IgG1 or IgG3 antibody.
6. The isolated antibody of claim 1 , wherein the antibody comprises at least one modification that enhances cell killing.
7. The isolated antibody of claim 6 , wherein the enhanced cell killing is enhanced antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC).
8. The isolated antibody of claim 6 , wherein the at least one modification is afucosylation.
9. The isolated antibody of claim 6 , wherein the at least one modification is one or more heavy chain constant regions mutations at one or more positions selected from L234, L235, G236, S239, F243, H268, D270, R292, S298, Y300, V305, K326, A330, I332, E333, K334, and P396.
10. The isolated antibody of claim 9 , wherein the one or more heavy chain constant A region mutations are one or more mutations selected from S239D, S239M, F243L, H268D, D270E, R292P, S298A, Y300L, V305I, K326D, A330L, A330M, I332E, E333A, K334A, K334E, and P396L.
11. The isolated antibody of claim 9 , wherein the one or more heavy chain constant region mutations are selected from: F243L/R292P/Y300L/V3051/P396L, S239D/1332E, S239D/1332E/A330L, S298A/E333A/K334A, 234Y/L235Q/G236W/S239M/H268D/D270E/S298 A, and D270E/K326D/A330M/K334E.
12. The isolated antibody of claim 6 , wherein the at least one modification is galactosylation.
13. The isolated antibody of claim 1 , wherein the antibody binds human CCR8 with an affinity (K D ) of less than 10 nM, but at least 15.9 pM.
14. The isolated antibody of claim 1 , wherein the antibody binds human CCR8 with an on-cell affinity (K D ) of less than 10 nM, but at least 15.9 pM.
15. The isolated antibody of claim 14 , wherein the on-cell affinity (K D ) is determined by Kinetic Exclusion Assay (KinExA).
16. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 92, and a light chain variable region (VL) comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 93.
17. The isolated antibody of claim 1 , wherein the antibody comprises a VH comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 96, and a VL comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 97.
18. The isolated antibody of claim 1 , wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 92, and a VL comprising the amino acid sequence of SEQ ID NO: 93.
19. The isolated antibody of claim 1 , wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 96, and a VL comprising the amino acid sequence of SEQ ID NO: 97.
20. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 94, and a light chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 95.
21. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 98, and a light chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 99.
22. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94, and a light chain comprising the amino acid sequence of SEQ ID NO: 95.
23. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 98, and a light chain comprising the amino acid sequence of SEQ ID NO: 99.
24. The isolated antibody of claim 1 , wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 84, and wherein the antibody is afucosylated.
25. The isolated antibody of claim 1 , wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 100, and wherein the antibody is afucosylated.
26. The isolated antibody of claim 1 , wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 92, and a VL comprising the amino acid sequence of SEQ ID NO: 93, and wherein the antibody is afucosylated.
27. The isolated antibody of claim 1 , wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 96, and a VL comprising the amino acid sequence of SEQ ID NO: 97, and wherein the antibody is afucosylated.
28. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94, and a light chain comprising the amino acid sequence of SEQ ID NO: 95, and wherein the antibody is afucosylated.
29. The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 98, and a light chain comprising the amino acid sequence of SEQ ID NO: 99, and wherein the antibody is afucosylated.